Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11921038 | 0.81 | MEN1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL12083455 | 0.71 | ALDH1A1 (0.36) | MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL9891022 | 0.71 | ALDH1A1 (0.36) | MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL11921037 | 0.68 | ALDH1A1 (0.40) | MEN1ALDH1A1KMT2AMAOAMAOB | |
| SCHEMBL13875989 | 0.68 | ALDH1A1 (0.37) | MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL19680274 | 0.67 | DPP4 (0.34) | MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL10110280 | 0.67 | — | — | |
| SCHEMBL12436168 | 0.67 | — | — | |
| SCHEMBL19752363 | 0.66 | GAA (0.33) | MEN1ALDH1A1POLBKMT2AMAPK13 | |
| SCHEMBL12085764 | 0.66 | ALOX12 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144869-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | UDC IRELAND LIMITED (IE) | 2022-05-12 | — | — | US | disclosed |
| US-11189806-B2 | Heteroleptic carbene complexes and the use thereof in organic electronics | UDC IRELAND LIMITED (IE) | 2021-11-30 | — | — | US | disclosed |
| US-20200373503-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2020-11-26 | — | — | US | disclosed |
| US-20120205645-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120205645-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-08-16 | — | — | US | disclosed |
| WO-2011051404-A1 | HETEROLEPTIC CARBENE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS | BASF SE (DE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120205645-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | OCIAD2, OCIAD1, CLTB | MEN1 3474/4885ALDH1A1 3051/4885POLB 1269/4885 |
| US-20220144869-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | OCIAD2, OCIAD1, CLTB | MEN1 3710/4885ALDH1A1 3145/4885POLB 1049/4885 |
| US-20200373503-A1 | HETEROLEPTIC CARBENE COMPLEXES AND THE USE THEREOF IN ORGANIC ELECTRONICS | OCIAD2, OCIAD1, CLTB | MEN1 3474/4885ALDH1A1 3051/4885POLB 1269/4885 |
| US-11189806-B2 | Heteroleptic carbene complexes and the use thereof in organic electronics | OCIAD2, OCIAD1, CLTB | MEN1 3474/4885ALDH1A1 3051/4885POLB 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.